Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho

Mizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $37.00 (from $32.00) while maintaining a Outperform rating.

The analyst commented: "Although there is one month remaining in 4Q25, Zoryve prescription trends have been stronger-than-expected, leading us to increase our sales forecast. We raise total sales from ~$109M to ~$113M (vs. ~$110M consensus) for 4Q25 and from $464M to $470M (vs. $467M consensus) for 2026, putting these estimates above consensus. We also have greater confidence in the potential of Zoryve to convert the steroidal market, and we raise our 2035 sales forecast from $1.54B to $1.65B. These changes increase our price target from $32 to $37. We reiterate Outperform on ARQT, as we see potential upside to our estimates."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)